CNBC
19 Jul 2026, 14:45 UTC · 15h ago
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
CNBC
19 Jul 2026, 14:45 UTC · 15h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Eli Lilly is acquiring clinical-stage psychedelic drug maker AtaiBeckley for up to $3.8 billion. — A multi-billion dollar acquisition by a Big Pharma giant validates the commercial viability of the psychedelic sector and signals a major shift in risk appetite.
+0.80Definium Therapeutics reported Phase 3 results for its LSD-based drug DT120 showing significant efficacy in treating major depressive disorder. — Successful Phase 3 data is a critical catalyst for drug approval and direct valuation increases for biotech firms.
+0.60President Trump issued an executive order in April to fast-track FDA reviews of psychedelic drugs. — Reduced regulatory timelines accelerate the path to monetization and lower the capital risk for developers in this space.
+0.50Continue reading
6 related stories
Top 3 movers · tap to explore
AtaiBeckley's lead asset, BPL-003, has received FDA Breakthrough Therapy Designation and is currently in Phase 3 trials. — Breakthrough status increases the likelihood of an expedited approval process for a potential $1-2 billion market opportunity.
+0.40The FDA previously denied approval for Lykos Therapeutics' MDMA-assisted therapy for PTSD in August 2024. — This serves as a reminder of the significant regulatory hurdles and binary risks associated with Schedule I substances.
-0.30Which stocks this story touches
Shares skyrocketed 50% following positive Phase 3 clinical trial results for its LSD-based drug DT120.
The company is expanding its portfolio into the high-potential psychedelic drug market via an acquisition.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
4h ago
